CHEYENNE, Wyoming, Feb. 24, 2017 /PRNewswire/ -- Xynomic Pharmaceuticals, Inc., an oncology drug research and development company, today announced that
To date a total of 14 Phase 1 and 2 clinical trials
"We are honored and excited to forge this landmark agreement. We will deploy necessary resources and closely work with KOLs to expeditiously bring this innovative drug to the market to address unmet medical needs," said Mr. Y. Mark Xu, Co-Founder, Chairman and CEO of Xynomic.
About Xynomic Pharmaceuticals, Inc.
A US company founded by seasoned biopharmaceutical executives and successful entrepreneurs, Xynomic focuses on in-licensing, developing and commercializing oncology drug candidates in US, Asia, EU and rest of the world. The founding executives worked at leading multinational biopharmaceutical companies (Schering, Eli Lilly, Merck and Roche) in R&D roles. The founders also had successful entrepreneurial experiences including founding, building and exiting successful US-China biopharmaceutical companies.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/xynomic-pharma-has-acquired-worldwide-rights-of-abexinostat--300413179.html
SOURCE Xynomic Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...View All